New TAVR Devices: Better Results in Bicuspids

Courtesy of del Dr. Carlos Fava.

 

sapien_xt_sapien_3 TAVR devicesThe bicuspid aortic valve is highly anatomically challenging because of valve asymmetric calcification, increased annulus diameter, raphe calcification and ascending aorta dilation. The new valves have shown to improve results, but we still lack data on this group.

 

301 patients presenting bicuspid aortic valve undergoing transcatheter aortic valve replacement (TAVR) were analyzed. 199 of these patients receive a first generation valve (FG) (Sapien XT: 87 y CoreValve: 112) and 102 a new generation valve (NG) (Sapien 3: 91 y Lotus: 11).

 

Populations were similar, except for ejection fraction, which resulted lower in those receiving NG (52.9% vs. 47.5%; p=0.004).

 

Device success rate was higher in those receiving NG:

NG: 92.2%

FG: 80.9%

[p=0.01]

 

Mild or severe paravalvular leak was also lower with NG:

NG: 0%

FG: 8.5%

[p=0.002]

 

There were no differences in:

  • Stroke
  • Life threatening bleeding
  • Major vascular complications
  • Kidney function deterioration
  • Safety end points
  • Cardiovascular or all-cause mortality in both groups at 30 days and one year (4.3% and 14.1%).

 

At multivariable analyzis, EuroSCORE ≥20, major bleeding and kidney function deterioration was associated to mortality (stages 2 or 3).

 

Conclusion

TAVR evolution in patients with bicuspid valve disease is favorable. New generation devices are associated with less paravalvular leak and higher device success.

 

Editorial Comment

This is the largest series to compare new generation devices against prior devices in this complex scenario to show they are beneficial in terms of device success and absence of paravalvular leak, with no differences in the rest of end points at one year.

 

Surely, at longer follow up, the presence of mild or severe paravalvular leak would translate into death.

 

Original Title: Transcatheter Aortic Valve Replacement with Early-and New-Generation Devices in Bicuspid Aortic valve Stenosis.

Reference: Sung-Han Yoon et al. J Am Coll Cardiol 2016;68:1195-205.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

We value your opinion. You are more than welcome to leave your comments, questions or suggestions here below.

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...